CureDuchenne Cares Session: Charleston, SC

  • Post author:
  • Post category:

CureDuchenne's Cares Sessions: Helping Connect and Inform Patient Families February 22nd, 2020, 6:30 pm The Sessions program from CureDuchenne is geared specifically towards patients and their families as well as…

Continue Reading CureDuchenne Cares Session: Charleston, SC
AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials
source: pixabay.com

AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials

AskBio Asklepios BioPharmaceuticals (AskBio) was first founded in 2001. It is based out of North Carolina.  This company is dedicated to the research of gene therapies as potential therapeutic options…

Continue Reading AskFirst: A New Collaborative Program to Support Rare Disease Patients in Gene Therapy Clinical Trials

CureDuchenne Professional Course: Houston, TX

  • Post author:
  • Post category:

A Professional Course for Healthcare Providers This course has been verified by the Texas PT for 6.5 CCUs. The professional course is a valuable opportunity for caregivers and healthcare providers…

Continue Reading CureDuchenne Professional Course: Houston, TX

CureDuchenne Cares Workshop: Houston, TX

  • Post author:
  • Post category:

CureDuchenne Cares Workshops: Hear The Latest From Experts February 8th, 2020, 8:00 am The Workshops program from CureDuchenne are day-long educational events that are oriented towards caregivers and Duchenne muscular…

Continue Reading CureDuchenne Cares Workshop: Houston, TX
Translarna Results in a Preserved Ability to Walk in Those with Duchenne Muscular Dystrophy
Fotorech / Pixabay

Translarna Results in a Preserved Ability to Walk in Those with Duchenne Muscular Dystrophy

PTC Therapeutics is a pharmaceutical company that has been working with Translarna, a medication intended for the treatment of Duchenne muscular dystrophy (DMD). They analyzed this treatment and presented the…

Continue Reading Translarna Results in a Preserved Ability to Walk in Those with Duchenne Muscular Dystrophy

CureDuchenne Cares Session: Salt Lake City, UT

  • Post author:
  • Post category:

CureDuchenne's Cares Sessions: Helping Connect and Inform Patient Families February 1st, 2020, 6:30 pm The Sessions program from CureDuchenne is geared specifically towards patients and their families as well as…

Continue Reading CureDuchenne Cares Session: Salt Lake City, UT

CureDuchenne Cares Session: Riverside, CA

  • Post author:
  • Post category:

CureDuchenne's Cares Sessions: Helping Connect and Inform Patient Families January 11th, 2020, 6:30 pm The Sessions program from CureDuchenne is geared specifically towards patients and their families as well as…

Continue Reading CureDuchenne Cares Session: Riverside, CA
Treatment for Duchenne Muscular Dystrophy with Rare Mutations Accepted Under Accelerated Approval
source: pixabay.com

Treatment for Duchenne Muscular Dystrophy with Rare Mutations Accepted Under Accelerated Approval

According to a story from BioSpace, the US Food and Drug Administration (FDA) has recently approved the drug golodirsen (marketed as Vyondys 53) as a treatment for Duchenne muscular dystrophy…

Continue Reading Treatment for Duchenne Muscular Dystrophy with Rare Mutations Accepted Under Accelerated Approval
A New Pediatric Precision Medicine Center is Opening in Utah
source: pixabay.com

A New Pediatric Precision Medicine Center is Opening in Utah

A new precision medicine center, specifically for pediatrics, has launched in Utah. This new center is the result of collaborative efforts from the Intermountain Primary Children's Hospital, Intermountain Precision Genomics,…

Continue Reading A New Pediatric Precision Medicine Center is Opening in Utah
Two Nonprofits Award $200,000 Grant for Development of Duchenne Muscular Dystrophy Patient Reported Outcomes
source: pixabay.com

Two Nonprofits Award $200,000 Grant for Development of Duchenne Muscular Dystrophy Patient Reported Outcomes

According to a story from PR Newswire, the nonprofit groups Duchenne UK and Parent Project Muscular Dystrophy (PPMD) have jointly awarded grant funding to the tune of $200,000 to Dr.…

Continue Reading Two Nonprofits Award $200,000 Grant for Development of Duchenne Muscular Dystrophy Patient Reported Outcomes
Study Analyzes New Outcome Measure for Duchenne Muscular Dystrophy
luvqs / Pixabay

Study Analyzes New Outcome Measure for Duchenne Muscular Dystrophy

According to a story from BioSpace, a global collaborative called the Trajectory Analysis Project recently released a study that utilized the North Star Ambulatory Assessment (NSAA), a recently developed measurement…

Continue Reading Study Analyzes New Outcome Measure for Duchenne Muscular Dystrophy

Steadman Philippon Research Institute Receives Award for Duchenne Muscular Dystrophy Research

According to a story from Financial Buzz, the Steadman Philippon Research Institute (SPRI) recently received an award in research from the National Institutes of Health (NIH). The award is in…

Continue Reading Steadman Philippon Research Institute Receives Award for Duchenne Muscular Dystrophy Research
Advocates for Duchenne Muscular Dystrophy Start Company Designed to Collect Data Directly From Patients
rawpixel / Pixabay

Advocates for Duchenne Muscular Dystrophy Start Company Designed to Collect Data Directly From Patients

According to a story from Xconomy, the US Food and Drug Administration (FDA) made a controversial decision three years ago when it approved the drug eteplirsen as a treatment for…

Continue Reading Advocates for Duchenne Muscular Dystrophy Start Company Designed to Collect Data Directly From Patients
Early Data Released From Phase 1B Duchenne Muscular Dystrophy Gene Therapy Trial
source: pixabay.com

Early Data Released From Phase 1B Duchenne Muscular Dystrophy Gene Therapy Trial

According to a story from BioPortfolio, the drug company Pfizer has recently presented data from its phase 1b clinical trial that tested the company's experimental gene therapy PF-06939926, which is…

Continue Reading Early Data Released From Phase 1B Duchenne Muscular Dystrophy Gene Therapy Trial
Duchenne Muscular Dystrophy and The Heart: Five Facts You Should Know
3dman_eu / Pixabay

Duchenne Muscular Dystrophy and The Heart: Five Facts You Should Know

According to a story from blog.cincinnatichildrens.org, a diagnosis of Duchenne muscular dystrophy is always an alarming piece of news; learning that your child has a progressive muscle atrophy disorder that…

Continue Reading Duchenne Muscular Dystrophy and The Heart: Five Facts You Should Know
Company Seeks Marketing Approval for Possible Duchenne Muscular Dystrophy Drug in EU
Capri23auto / Pixabay

Company Seeks Marketing Approval for Possible Duchenne Muscular Dystrophy Drug in EU

According to a story from BioPortfolio, the specialty pharmaceutical company Santhera Pharmaceuticals recently announced that it has submitted its marketing application to the European Medicines Agency (EMA) for its drug…

Continue Reading Company Seeks Marketing Approval for Possible Duchenne Muscular Dystrophy Drug in EU

Program Established by the NIH to Help Rare Disease Advocacy Groups Start Patient Registries

The Beginnings Anne Pariser worked for 16 years at the FDA. For part of that time, she was a team leader for the Center for Drug Evaluation and Research where…

Continue Reading Program Established by the NIH to Help Rare Disease Advocacy Groups Start Patient Registries

After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear

According to a story from BioSpace, a Phase 1/2 clinical trial testing SGT-001, an investigational treatment for Duchenne muscular dystrophy, has been plagued by problems with side effects and adverse…

Continue Reading After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear

After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear

According to a story from BioSpace, a Phase 1/2 clinical trial testing SGT-001, an investigational treatment for Duchenne muscular dystrophy, has been plagued by problems with side effects and adverse…

Continue Reading After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear
Duchenne Muscular Dystrophy Patient That Admired Stephen Hawking Passed Away During Exams…With Close to Perfect Scores
HarinathR / Pixabay

Duchenne Muscular Dystrophy Patient That Admired Stephen Hawking Passed Away During Exams…With Close to Perfect Scores

According to a story from m.dailyhunt.in, Vinayak Sreedhar, an Indian student with Duchenne muscular dystrophy, passed away in the midst of taking his exams. Vinayak was a driven and highly…

Continue Reading Duchenne Muscular Dystrophy Patient That Admired Stephen Hawking Passed Away During Exams…With Close to Perfect Scores

Orphan Drug Designation Granted for Potential Duchenne Muscular Dystrophy Treatment

For years FibroGen has been investigating a drug called pamrevlumab. They believe it could be an effective treatment for Duchenne muscular dystrophy (DMD), pancreatic cancer, and idiopathic pulmonary fibrosis (IPF).…

Continue Reading Orphan Drug Designation Granted for Potential Duchenne Muscular Dystrophy Treatment
Company Announces Plans for Myotonic Dystrophy and Duchenne Muscular Dystrophy Treatments
rawpixel / Pixabay

Company Announces Plans for Myotonic Dystrophy and Duchenne Muscular Dystrophy Treatments

According to a story from CRWE World, the genetic medicines company Audentes Therapeutics has recently announced its intent to develop new therapies for myotonic dystrophy and Duchenne muscular dystrophy. These…

Continue Reading Company Announces Plans for Myotonic Dystrophy and Duchenne Muscular Dystrophy Treatments